Medpace Holdings (NASDAQ:MEDP) reported a strong Q2 CY2025, with revenue reaching $603.3 million—up 14.2% year-on-year and surpassing analysts’ expectations of $542 million. The company raised its full-year revenue guidance to $2.47 billion, which is 13% above estimates, and reported a GAAP profit of $3.10 per share, also above consensus estimates. This growth was attributed to reduced project cancellations, improved client funding, and a shift towards faster-executing clinical trials, particularly in metabolic areas. Looking ahead, Medpace expects this momentum to continue, contingent on stable cancellation rates and effective scaling of operations. The stock has seen significant growth, trading at $482.97 compared to $308.94 prior to earnings.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://stockstory.org/us/stocks/nasdaq/medp/news/earnings-call/medp-q2-deep-dive-backlog-conversion-lower-cancellations-and-therapeutic-mix-drive-outlook
